The global U.S. Influenza Vaccines market size is expected to reach USD 13.31 billion by 2030, registering a CAGR of 16.3% from 2023 to 2030, according to a new report by Coherent Market Insights Inc.
The respiratory system is affected by influenza. Although the flu itself is usually harmless, its complications can be fatal. Sneezing, a runny nose, and a sore throat at first glance are all symptoms of the common cold. Symptoms of a cold, such as a high body temperature, a sore head, difficulty breathing, shivering, and sweating, develop gradually before suddenly striking. The flu virus is spread primarily through the airborne droplets produced when infected people cough, sneeze, or speak. Someone who touches an infected surface or object may then inhale the droplets into their lungs. A flu shot, while not as effective as it once was still lessens the likelihood of life-threatening complications from the disease.
The expansion of the U.S. market for influenza vaccines is anticipated to be driven by an increase in inorganic growth strategies, like product consent from regulatory authorities like the Food and Drug Administration. For example, in February 2021, pharmaceutical company Seqirus USA Inc. announced that their Fluad Quadrivalent vaccine, the first adjuvanted quadrivalent influenza vaccine for adults 65 and older, had been approved by the U.S. Food and Drug Administration. A stronger and more widespread immune response against influenza will result from this vaccine.
Request Sample Report + All Related Graphs & Charts:
https://www.coherentmarketinsights.com/insight/request-sample/1127
We have an updated report [Version – 2023] available.
(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)
Our Sample Report May Includes:
• 2030 Updated Report Introduction, Overview, and In-depth industry analysis.
• 100+ Pages Research Report (Inclusion of Updated Research).
• Provide Chapter-wise guidance on Requests.
• 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
• Includes Updated List of tables & figures.
• Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.
Top Key Players:
★ Seqirus USA Inc.
★ GSK plc.
★ Sanofi
★ Pfizer Inc.
★ AstraZeneca
★ Novartis AG
★ Merck & Co. Inc.
★ Protein Sciences Corporation
★ Moderna Inc.
★ INOVIO Pharmaceuticals
★ Novavax
★ EMERGENT
Over a hundred countries have reported cases of COVID-19 since the outbreak in December 2019, and on January 30, 2020, the World Health Organization declared the situation a global public health emergency.
Three major ways in which COVID-19 can affect the economy are through its effects on the production and demand of drugs, its disruption of distribution channels, and its monetary impact on businesses and financial markets. China, India, Saudi Arabia, the United Arab Emirates, Egypt, and other countries are experiencing difficulties with drug transportation as a result of nationwide lockdowns.
However, the rise in influenza vaccination rates during the COVID-19 pandemic was good news for the market for influenza vaccines in the United States. For instance, the number of people getting vaccinated against the flu rose by 9% in the final quarter of 2020, according to data published by the Centers for Disease Control and Prevention in December 2021. Vaccination rates increased by 13% among adolescents and 15% among adults aged 18 to 64 in the United States. Reduce respiratory illness, safeguard vital personnel, and save money on care for COVID-19 patients by getting vaccinated.
The market for influenza vaccines in the United States is anticipated to be driven by the acceptance of inorganic growth strategies like product approval from regulatory authorities such as the Food and Drug Administration. In October 2021, for example, pharmaceutical firm Seqirus USA Inc. announced that their Quadrivalent Influenza Vaccine for Children Ages 6 Months and Older had been approved by the United States Food and Drug Administration. The first cell-based influenza vaccine in the United States, quadrivalent influenza vaccine has the potential to be more effective than previous influenza vaccines.
The expansion of the U.S. market for influenza vaccines is anticipated to be stymied by a lack of vaccine supply over the forecast period. For example, in October 2020, the United States experienced a shortage of influenza vaccines, as reported by the Center for Infectious Disease Research and Policy (CIDRAP). Manufacturing or production issues, insufficient stockpiles, led to the vaccine shortage.
Highlights the following Key Factors:
𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐝𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧: A detailed description of the company’s operations and business divisions.
𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲: Analyst’s summarization of the company’s business strategy.
𝐒𝐖𝐎𝐓 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬: A detailed analysis of the company’s strengths, weakness, opportunities and threats.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐡𝐢𝐬𝐭𝐨𝐫𝐲: Progression of key events associated with the company.
𝐌𝐚𝐣𝐨𝐫 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬 𝐚𝐧𝐝 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬: A list of major products, services and brands of the company.
𝐊𝐞𝐲 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐨𝐫𝐬: A list of key competitors to the company.
𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐥𝐨𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐬𝐮𝐛𝐬𝐢𝐝𝐢𝐚𝐫𝐢𝐞𝐬: A list and contact details of key locations and subsidiaries of the company.
𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐫𝐚𝐭𝐢𝐨𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐩𝐚𝐬𝐭 𝐟𝐢𝐯𝐞 𝐲𝐞𝐚𝐫𝐬: The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
We Offer Customized Report, Click:
https://www.coherentmarketinsights.com/insight/request-customization/1127
Key Highlights Market Study:
Revenue and Sales Estimation: Historical Revenue and sales volume is presented and further data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast numbers for key regions covered in the report along with classified and well recognized Types and end-use industry. Additionally macroeconomic factor and regulatory policies are ascertained in U.S. Influenza Vaccines industry evolution and predictive analysis.
Manufacturing Analysis: The report is currently analysed concerning various product type and application. The U.S. Influenza Vaccines market provides a chapter highlighting manufacturing process analysis validated via primary information collected through Industry experts and Key officials of profiled companies.
Competition: Leading players have been studied depending on their company profile, product portfolio, capacity, product/service price, sales, and cost/profit.
Demand & Supply and Effectiveness: U.S. Influenza Vaccines report additionally provides distribution, Production, Consumption & Export & Import
Purchasing the U.S. Influenza Vaccines Market:
➣ Outlook for the worldwide U.S. Influenza Vaccines market in both developed and emerging markets, both now and in the future.
➣ Both the market segment with the largest projected share and the market segment with the highest CAGR throughout the projection period.
➣ Countries and regions anticipated to experience the fastest development throughout the projected period.
➣ The most recent innovations, market shares, and business tactics used by the key market participants.
➣ Study examines emerging market trends as well as the likelihood that various trends will impact expansion.
➣ Analysis also discusses the factors, challenges, and opportunities that will have a significant impact on the global U.S. Influenza Vaccines industry.
➣ Research includes a detailed analysis of market statistics as well as historical and current growth conditions in order to provide futuristic growth estimates.
Purchase This Complete Business Report:
https://www.coherentmarketinsights.com/insight/buy-now/1127
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 U.S. Influenza Vaccines Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: U.S. Influenza Vaccines Industry Impact
Chapter 2 Global U.S. Influenza Vaccines Competition by Types, Applications, and Top Regions and Countries
2.1 Global U.S. Influenza Vaccines (Volume and Value) by Type
2.3 Global U.S. Influenza Vaccines (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global U.S. Influenza Vaccines Sales, Consumption, Export, Import by Regions (2017-2023)
Chapter 5 North America U.S. Influenza Vaccines Market Analysis
Chapter 6 East Asia U.S. Influenza Vaccines Market Analysis
Chapter 7 Europe U.S. Influenza Vaccines Market Analysis
Chapter 8 South Asia U.S. Influenza Vaccines Market Analysis
Chapter 9 Southeast Asia U.S. Influenza Vaccines Market Analysis
Chapter 10 Middle East U.S. Influenza Vaccines Market Analysis
Chapter 11 Africa U.S. Influenza Vaccines Market Analysis
Chapter 12 Oceania U.S. Influenza Vaccines Market Analysis
Chapter 13 South America U.S. Influenza Vaccines Market Analysis
Chapter 14 Company Profiles and Key Figures in U.S. Influenza Vaccines Business
Chapter 15 Global U.S. Influenza Vaccines Market Forecast (2023-2030)
Chapter 16 Conclusions
Explore More Related Insights:
Microneedle flu vaccine market
Plasmid dna manufacturing market
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame
CA 94010, United States
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
JAPAN: +81-50-5539-1737
INDIA: +91-848-285-0837